EdgeMarket › What Deerfield Management Company, L.P. (Series C) reported owning
What Deerfield Management Company, L.P. (Series C) reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
8.5BPositions
82Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| unmapped CUSIP 670703107 | 1.8B | 20.8% | 17.2M | — | — |
| unmapped CUSIP 112463AF1 | 505.4M | 6.0% | 306.9M | — | — |
| COGT Cogent Biosciences, Inc. | 348.1M | 4.1% | 9.0M | 36.73 | +209.6% |
| PRAX Praxis Precision Medicines, Inc. | 310.4M | 3.7% | 963.4K | 375.94 | +730.8% |
| VTRS Viatris Inc | 273.0M | 3.2% | 20.2M | 16.32 | +53.2% |
| UTHR UNITED THERAPEUTICS Corp | 271.0M | 3.2% | 457.0K | 513.12 | +67.4% |
| RVMD Revolution Medicines, Inc. | 223.4M | 2.6% | 2.3M | 209.46 | +479.3% |
| unmapped CUSIP 604749AB7 | 209.4M | 2.5% | 70.0M | — | — |
| unmapped CUSIP 04280AAC4 | 207.2M | 2.4% | 200.0M | — | — |
| CELC Celcuity Inc. | 195.6M | 2.3% | 1.7M | 93.53 | +91.8% |
| CNC CENTENE CORP | 193.7M | 2.3% | 5.9M | 65.02 | +121.2% |
| LRMR Larimar Therapeutics, Inc. | 160.2M | 1.9% | 35.6M | 4.18 | +10.9% |
| BKD Brookdale Senior Living Inc. | 159.2M | 1.9% | 11.6M | 11.80 | +61.4% |
| VERA Vera Therapeutics, Inc. | 149.7M | 1.8% | 3.7M | 32.27 | +46.0% |
| IONS IONIS PHARMACEUTICALS INC | 148.7M | 1.8% | 2.0M | 59.74 | +39.5% |
| BCRX BIOCRYST PHARMACEUTICALS INC | 143.2M | 1.7% | 15.0M | 9.55 | +14.0% |
| INSP Inspire Medical Systems, Inc. | 139.4M | 1.6% | 2.7M | 62.36 | -33.0% |
| LEGN Legend Biotech Corp | 139.1M | 1.6% | 7.7M | 21.82 | -38.8% |
| AHCO AdaptHealth Corp. | 136.6M | 1.6% | 11.5M | 5.63 | -39.7% |
| NAMS NewAmsterdam Pharma Co N.V. | 136.5M | 1.6% | 4.3M | 27.87 | +14.6% |
| ACHC Acadia Healthcare Company, Inc. | 105.7M | 1.2% | 4.5M | 27.82 | +30.6% |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | 98.6M | 1.2% | 1.6M | 87.11 | +331.2% |
| unmapped CUSIP 14888U101 | 97.6M | 1.2% | 3.9M | — | — |
| INDV Indivior Pharmaceuticals, Inc. | 94.4M | 1.1% | 3.1M | 36.87 | +52.7% |
| XENE Xenon Pharmaceuticals Inc. | 94.0M | 1.1% | 1.6M | 60.77 | +61.5% |
| unmapped CUSIP 462222AF7 | 90.6M | 1.1% | 60.0M | — | — |
| PHVS Pharvaris N.V. | 88.3M | 1.0% | 3.1M | 36.27 | +57.7% |
| SNDX Syndax Pharmaceuticals Inc | 88.3M | 1.0% | 3.8M | 19.65 | +24.8% |
| TNGX Tango Therapeutics, Inc. | 86.8M | 1.0% | 4.1M | 23.88 | +253.8% |
| unmapped CUSIP 01625VAB0 | 85.9M | 1.0% | 61.0M | — | — |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 85.6M | 1.0% | 1.0M | 111.10 | +374.4% |
| PFE PFIZER INC | 85.4M | 1.0% | 3.0M | 28.07 | +10.6% |
| NBIX NEUROCRINE BIOSCIENCES INC | 80.4M | 0.9% | 610.0K | 152.57 | +14.5% |
| unmapped CUSIP 23954D109 | 79.8M | 0.9% | 3.7M | — | — |
| SVRA Savara Inc | 74.1M | 0.9% | 13.6M | 5.59 | +80.9% |
| unmapped CUSIP 98937LAA3 | 67.3M | 0.8% | 65.0M | — | — |
| unmapped CUSIP 29332G102 | 66.9M | 0.8% | 4.7M | — | — |
| unmapped CUSIP 64049MAB6 | 66.7M | 0.8% | 72.7M | — | — |
| GMAB GENMAB A/S | 66.1M | 0.8% | 2.5M | 33.45 | +39.0% |
| BIO BIO-RAD LABORATORIES, INC. | 63.0M | 0.7% | 226.1K | 380.03 | +31.9% |
| LNTH Lantheus Holdings, Inc. | 62.8M | 0.7% | 828.0K | 99.97 | +78.1% |
| SPRY ARS Pharmaceuticals, Inc. | 60.3M | 0.7% | 7.5M | 5.50 | -62.3% |
| STOK Stoke Therapeutics, Inc. | 59.4M | 0.7% | 1.8M | 32.29 | +67.1% |
| NVST Envista Holdings Corp | 56.1M | 0.7% | 2.2M | 27.20 | +31.3% |
| IDYA IDEAYA Biosciences, Inc. | 51.0M | 0.6% | 1.5M | 39.67 | +63.1% |
| BLTE BELITE BIO, INC | 48.5M | 0.6% | 304.0K | 161.06 | +154.0% |
| BMRN BIOMARIN PHARMACEUTICAL INC | 48.1M | 0.6% | 851.6K | 66.70 | +15.1% |
| KYMR Kymera Therapeutics, Inc. | 46.7M | 0.6% | 561.2K | 119.80 | +182.9% |
| CERT Certara, Inc. | 44.5M | 0.5% | 7.8M | 8.43 | -21.1% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 43.7M | 0.5% | 4.9M | 9.08 | -5.7% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →